Barclays Has Lowered Expectations for Certara (NASDAQ:CERT) Stock Price

by · The Cerbat Gem

Certara (NASDAQ:CERT – Get Free Report) had its price target lowered by equities researchers at Barclays from $14.00 to $12.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Barclays‘s price objective indicates a potential upside of 8.79% from the company’s previous close.

Several other research analysts also recently issued reports on the stock. KeyCorp lowered their price objective on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Friday, September 27th. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. Finally, Robert W. Baird decreased their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Certara presently has an average rating of “Hold” and an average target price of $15.92.

Check Out Our Latest Stock Analysis on Certara

Certara Stock Up 0.4 %

Certara stock traded up $0.04 during trading on Thursday, reaching $11.03. The stock had a trading volume of 1,081,810 shares, compared to its average volume of 786,430. Certara has a 52-week low of $9.99 and a 52-week high of $19.87. The business has a 50 day moving average price of $11.02 and a 200 day moving average price of $13.70. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28. The stock has a market cap of $1.77 billion, a PE ratio of -22.06, a P/E/G ratio of 4.88 and a beta of 1.51.

Certara (NASDAQ:CERT – Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company’s revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.06 EPS. On average, analysts predict that Certara will post 0.27 EPS for the current year.

Insider Activity at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at $552,503.73. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the transaction, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at $552,503.73. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Certara

Several hedge funds have recently bought and sold shares of the stock. Landscape Capital Management L.L.C. purchased a new position in Certara during the third quarter worth $852,000. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in Certara during the third quarter worth $1,513,000. Quest Partners LLC purchased a new position in Certara during the third quarter worth $367,000. Zions Bancorporation N.A. grew its position in shares of Certara by 18.5% in the third quarter. Zions Bancorporation N.A. now owns 76,811 shares of the company’s stock valued at $899,000 after purchasing an additional 11,995 shares during the period. Finally, KBC Group NV grew its position in shares of Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after purchasing an additional 1,584 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

(Get Free Report)

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

See Also